<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22965" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hollenhorst Plaque</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kaufman</surname>
            <given-names>Evan J.</given-names>
          </name>
          <aff>University of Virginia Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mahabadi</surname>
            <given-names>Navid</given-names>
          </name>
          <aff>A.T. Still University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Munakomi</surname>
            <given-names>Sunil</given-names>
          </name>
          <aff>Kathmandu University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Bhupendra C.</given-names>
          </name>
          <aff>University of Utah</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Evan Kaufman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Navid Mahabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sunil Munakomi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bhupendra Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22965.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hollenhorst plaques, named after the American ophthalmologist Robert Hollenhorst, are microscopic cholesterol emboli that can be found in the small blood vessels of the retina. These tiny, yellowish fragments typically originate from atherosclerotic plaques in larger arteries, breaking off and traveling through the bloodstream until lodging in the retinal vessels. Hollenhorst plaques are often associated with systemic vascular diseases, particularly atherosclerosis, and their presence in the retinal circulation can have significant implications for the patient's overall health. Identifying these plaques during a retinal examination is crucial, as it may serve as a clinical indicator of underlying cardiovascular conditions, prompting further investigation and intervention to manage the patient's vascular health. Understanding the significance of Hollenhorst plaques is essential for healthcare professionals in ophthalmology, cardiology, and general medicine, as it underscores the interconnectedness of ocular and systemic health.</p>
        <p>This activity provides a comprehensive exploration of Hollenhorst plaques, spanning presentation recognition, evaluation, and management. The paramount role of Hollenhorst plaques as the primary cause of ocular ischemic syndrome post-retinal artery occlusion will be reviewed.&#x000a0;Participants gain insights into improving patient outcomes and aligning management strategies with evolving standards in the field.&#x000a0;The critical importance of an interprofessional team approach in delivering optimal care to affected patients will also be addressed.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Assess patients for the presence of Hollenhorst plaques, considering risk factors such as age, hypertension, and atherosclerosis to enable early detection and intervention.</p></list-item><list-item><p>Differentiate between Hollenhorst plaques and other retinal pathologies during ocular examinations, utilizing diagnostic skills to accurately identify these cholesterol emboli.</p></list-item><list-item><p>Implement evidence-based strategies for managing patients with Hollenhorst plaques, including initiating appropriate medical interventions and referrals to specialists in cardiology and vascular medicine for comprehensive care.</p></list-item><list-item><p>Collaborate with&#x000a0;an interprofessional team&#x000a0;to ensure a multidisciplinary approach to managing patients with Hollenhorst plaques, addressing both ocular and systemic aspects of their health.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22965&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22965">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22965.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Stroke is the third most common cause of death in the United States. Eighty percent of all strokes are due to vessel occlusion secondary to atherothrombosis or embolus.&#x000a0;Hollenhorst plaque (HP) was discovered in 1961 by Dr. Robert Hollenhorst. He defined them as tiny emboli caused by cholesterol plaques and found in the retina's small blood vessels.&#x000a0;The appearance of these emboli indicates that they are yellow, refractile, and typically located&#x000a0;at an arterial bifurcation.<xref ref-type="bibr" rid="article-22965.r1">[1]</xref><xref ref-type="bibr" rid="article-22965.r2">[2]</xref> Hollenhorst plague is the most common cause accounting for the ocular ischemic syndrome (OIS) following retinal artery occlusion (RAO).<xref ref-type="bibr" rid="article-22965.r3">[3]</xref></p>
        <p>
<bold>History</bold>
</p>
        <p>In 1927, T. Harrison Butler first mentioned a bright retinal embolus involving the inferior temporal arteriole. Hollenhorst, Witmer, and Schmid described this lesion in 1958.<xref ref-type="bibr" rid="article-22965.r4">[4]</xref>&#x000a0;Hollenhorst postulated that the cholesterol ester is the fundamental component of the lesion, and he proposed a temporal relationship, foreseeing the risk of subsequent cerebral ischemic events on the side ipsilateral to symptomatic carotid disease. He also confirmed that this plague was mobile upon manual ocular pressure.<xref ref-type="bibr" rid="article-22965.r4">[4]</xref>&#x000a0;In 1961, Hollenhorst detailed the characteristics of these vivid, orange-appearing plaques in his paper titled "Significance of Bright Plaques in Retinal Arterioles." These plaques were identified in 11% of cohorts with carotid disease and 4% with vertebrobasilar diseases.&#x000a0;The plaques rarely obstruct arterioles, instead frequently migrating to distal vessels and ultimately dissipating through fragmentation.<xref ref-type="bibr" rid="article-22965.r4">[4]</xref> Hollenhorst and Jack Whisnant reproduced retinal plaques mirroring those observed in humans through the injection of cholesterol crystals and human atheromatous material into the carotids of experimental animals. This was validated in 1963 from an autopsy of a patient who had similar appearing retinal plaques and who had died following carotid endarterectomy (CEA).<xref ref-type="bibr" rid="article-22965.r4">[4]</xref></p>
      </sec>
      <sec id="article-22965.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>HPs tend to&#x000a0;originate from carotid arteries or the aorta. This finding is consistent with carotid disease originating from atherosclerotic lesions. Upon discovering an HP, eye care professionals initially assumed&#x000a0;that it originated from the stenosed, ipsilateral internal carotid artery (ICA). The direct anatomical route between the ICA and the central retinal artery (CRA) supports this assumption. The ophthalmic artery is the first branch of the ICA, which then leads into the CRA.<xref ref-type="bibr" rid="article-22965.r5">[5]</xref><xref ref-type="bibr" rid="article-22965.r6">[6]</xref></p>
      </sec>
      <sec id="article-22965.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The Blue Mountains Eye study stated that the prevalence of retinal emboli is 1.4% in the general population older than 49 years.<xref ref-type="bibr" rid="article-22965.r7">[7]</xref> The prevalence increases with age. Retinal emboli are significantly more prevalent in men than in women. HPs make up&#x000a0;80% of retinal emboli. An estimated 10% of carotid emboli reach the retinal arteries.<xref ref-type="bibr" rid="article-22965.r8">[8]</xref></p>
        <p>In the Beaver Dam Eye Study, comprising almost 5000 patients, the prevalence of HPs was 1.3%, and the 5-year incidence was 0.9%.<xref ref-type="bibr" rid="article-22965.r9">[9]</xref>&#x000a0;In a study of 130 consecutive patients with a diagnosis of HP alongside central or branch RAO, the mean age of the patients was 68 &#x000b1; 16 years, and the incidence of symptomatic patients was 61%.<xref ref-type="bibr" rid="article-22965.r10">[10]</xref></p>
        <p>The incidence of asymptomatic retinal emboli is 1.4%. Cholesterol emboli are more prevalent in men than women (2.2% vs 0.8%).<xref ref-type="bibr" rid="article-22965.r11">[11]</xref><xref ref-type="bibr" rid="article-22965.r12">[12]</xref>&#x000a0;Eighty percent of all retinal emboli are of the cholesterol type.<xref ref-type="bibr" rid="article-22965.r4">[4]</xref><xref ref-type="bibr" rid="article-22965.r11">[11]</xref> Significant links with hypertension (odds ratio [OR], -2.2), vascular disease (OR, -2.4), past vascular surgery (OR, -3.5), and current smoking history (OR, -2.2) or any smoking history (OR, -2.6) have been observed.<xref ref-type="bibr" rid="article-22965.r11">[11]</xref></p>
      </sec>
      <sec id="article-22965.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Ulcerated plaques just distal to the bifurcation of the common carotid artery into its external and internal branches may be a source of retinal emboli that can be asymptomatic or produce transient monocular blindness.<xref ref-type="bibr" rid="article-22965.r13">[13]</xref><xref ref-type="bibr" rid="article-22965.r14">[14]</xref> Cholesterol plaques are seen in the retina owing to their relatively small size and decreased velocity while traveling through the internal carotid system.</p>
      </sec>
      <sec id="article-22965.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>HP is a marker of past embolic events but is a poor predictor of future events. These plaques may or may not cause an RAO. The discovery of asymptomatic emboli has a greater concern for a patient&#x02019;s systemic health than visual health. Most&#x000a0;HPs are discovered incidentally during funduscopy. They often dislodge and are not noted on subsequent fundus examinations.</p>
        <p>An HP is a clinical sign, commonly a contributing factor in diagnosing RAO. The plaque must completely obstruct the vessel for an HP to cause an RAO.&#x000a0;RAOs can occur in the central retinal artery (CRAO) or one of its branches (BRAO). HP is a possible&#x000a0;cause of a CRAO/BRAO and should not be considered synonymous.</p>
        <p>As&#x000a0;noted in the differential diagnosis, other types of emboli can occlude the relevant vessels. There are also nonembolic causes of RAO, including nocturnal arterial hypotension and transient vasospasm. HP, like other types of retinal emboli, may not stay in&#x000a0;1 place. The plaque may dislodge and move to a smaller diameter vessel before it gets lodged again, or the plaque may dissolve completely. The presence of an HP is a confirming diagnosis; however, the absence of a plaque does not rule out the possibility of embolic occlusion.</p>
        <p>If an RAO occurs, the most common symptom is sudden, painless vision loss. The fundus will display typical ischemic signs, such as retinal whitening around the occluded vessel (see <bold>Images.</bold> Hollenhorst Plaques). The macular area will remain &#x0201c;cherry-red&#x0201d; due to its secondary outer retinal blood supply. If the plaque only partially occludes the vessel, blood can still flow through the lumen, and no damage occurs. A single eye can undergo more than&#x000a0;1 transient RAO.&#x000a0;</p>
      </sec>
      <sec id="article-22965.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnostic tools which may be employed in the evaluation of HPs include the following:</p>
        <p><bold>Auscultation of the ipsilateral carotid</bold> for the presence of a bruit.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
        <p><bold>Blood pressure measurement</bold> to rule out hypertension or hypotension.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <p><bold>Electrocardiogram (ECG)</bold> for atrial fibrillation (AF).&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
        <p><bold>Carotid duplex study- </bold>A&#x000a0;significant stenosis is characterized by a diameter reduction of 80% to 99%, a peak systolic velocity of &#x0003e;125cm/sec, and an end-diastolic velocity of&#x0003e;140cm/sec alongside extensive spectral broadening. Carotid bifurcation stenosis was &#x0003c;30% in 68% of the patients, between 30% and 60% in 22% of the patients, and &#x0003e;60% in only 8% of the patients.<xref ref-type="bibr" rid="article-22965.r10">[10]</xref> Significant carotid internal artery stenosis was detected in 7% to 20% of patients with asymptomatic retinal emboli and 20% to 25% of patients with BRAOs.<xref ref-type="bibr" rid="article-22965.r15">[15]</xref>&#x000a0;&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
        <p><bold>Echocardiography (ECHO)</bold> study for determining the cardio-embolic source.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <p><bold>CT or MRI 4-vessel carotid angiography</bold> to evaluate for stenosis, dissection, and/or dysplasia. CT angiography has a sensitivity of 85% and a specificity of 93%.<xref ref-type="bibr" rid="article-22965.r16">[16]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <p><bold>Blood test</bold> for ruling out any hypercoagulopathy.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
        <p><bold>Fluorescein angiography </bold>shows delayed or absent fill in the retinal artery (most specific sign), prolonged arteriovenous transit time (most sensitive sign), and capillary nonperfusion (loss of endothelial cells, pericytes, and lumen obliteration). Staining of retinal vessels (endothelial cell damage due to chronic ischemia), macular edema, and hyperfluorescence within the optic disk in OIS are also observed, caused by leakage from the disk and capillaries.<xref ref-type="bibr" rid="article-22965.r3">[3]</xref><xref ref-type="bibr" rid="article-22965.r17">[17]</xref> Indocyanine green angiography shows prolonged arm-to-choroid and intrachoroidal circulation times and slow filling of the watershed zones.<xref ref-type="bibr" rid="article-22965.r3">[3]</xref></p>
        <p><bold>Visual-evoked potentials (VEP), electroretinography (ERG), and ophthalmo-tonometry</bold> are seldom used.<xref ref-type="bibr" rid="article-22965.r3">[3]</xref> Electroretinography shows reduced amplitudes of both the a- and b-waves.<xref ref-type="bibr" rid="article-22965.r18">[18]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
        <p><bold>Optical coherence tomography (OCT)</bold>&#x000a0;shows thick, hyperreflective inner retinal layers with blocked outer retina reflectivity. Eventually, the retina is thinned out and appears atrophic. This also demonstrates a reduction in the foveal avascular zone and improved vessel density in all retinal layers after carotid artery stenting for OIS.<xref ref-type="bibr" rid="article-22965.r19">[19]</xref></p>
        <p><bold>B-scan ultrasonography or orbital computed tomography (CT)</bold> scan to rule out compressive lesions.</p>
      </sec>
      <sec id="article-22965.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p><bold>Immediate ocular massage</bold> may help dislodge the emboli.<xref ref-type="bibr" rid="article-22965.r17">[17]</xref> Irreversible retinal damage occurs within 240 minutes of central RAO.</p>
        <p><bold>Surgical embolus removal</bold> was first attempted in 1990 by Peyman and Gremillion. This was achieved in 87.5% with reperfusion and improved visual acuity in 4 of 6 patients in&#x000a0;1 study.<xref ref-type="bibr" rid="article-22965.r17">[17]</xref></p>
        <p>The treatment decision for carotid stenosis is primarily based on the degree of stenosis and associated symptomatology.</p>
        <p><bold>For patients with &#x0003c;50% stenosis&#x000a0;</bold>- antiplatelet therapy is advocated in the form of:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cyclooxygenase-2 (COX-2) inhibitor- Aspirin</p>
          </list-item>
          <list-item>
            <p>Adenosine diphosphate (ADP) receptor inhibitor- Clopidogrel and</p>
          </list-item>
          <list-item>
            <p>ADP reuptake inhibitor- Dipyridamole</p>
          </list-item>
        </list>
        <p>This minimizes the risk of a 5-year stroke rate by almost 50%. Subgroup analysis in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial revealed that atorvastatin reduced the risk of both cerebrovascular and cardiovascular adverse events.<xref ref-type="bibr" rid="article-22965.r20">[20]</xref></p>
        <p><bold>For patients with &#x0003e;70% stenosis - </bold>are considered for surgical interventions in the form of either CEA or carotid angioplasty and stenting (CAS). Both are safe and effective, with increased odds of myocardial infarction following CEA and an increased risk of stroke following CAS. They also have a comparable risk for fatal or disabling stroke.<xref ref-type="bibr" rid="article-22965.r21">[21]</xref> Evidence is poor for purely ocular&#x000a0;transient ischemic attacks (TIAs).</p>
        <p>North American Symptomatic Carotid Endarterectomy Trial (NASCET) showed that surgical intervention was markedly effective with cohorts with 70% to 99% stenosis.<xref ref-type="bibr" rid="article-22965.r22">[22]</xref>&#x000a0;This significantly reduced the 2-year risk of ipsilateral stroke rate compared to medical management alone (9% vs 26%)&#x000a0; among symptomatic cohorts presenting with transient monocular visual loss, transient ischemic attack, or nondisabling strokes. Comparable findings were observed among symptomatic patients within the European Carotid Surgical Trial.<xref ref-type="bibr" rid="article-22965.r23">[23]</xref> A meta-analysis comprising 5223 patients with asymptomatic moderate to severe stenosis and low perioperative risks favored CEA (relative risk, 0.69). CAS is also comparable to endarterectomy in terms of risk of procedural stroke (2.9 vs 1.7%) and survival (87.1% vs 89.4%). The 5-year stroke-free survival was similar (93.1% vs 94.7%).<xref ref-type="bibr" rid="article-22965.r24">[24]</xref></p>
        <p><bold>For patients with 50% to 69% stenosis&#x000a0;</bold>- there was a considerable drop in the benefits following surgery.</p>
        <p>The Asymptomatic Carotid Atherosclerosis Study and Asymptomatic Carotid Surgery Trial showed a risk reduction of 53% and 46% among cohorts with 60% stenosis with CEA.<xref ref-type="bibr" rid="article-22965.r25">[25]</xref> Guidelines recommend CEA when the risk of perioperative stroke, myocardial infarction, or mortality is considerably low.</p>
        <p>No ocular treatment is necessary unless an HP completely obstructs a vessel, causing an RAO. All patients with retinal emboli should be referred to the patient&#x02019;s primary care provider for a bilateral carotid duplex study. The management considers the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Patient education on HA as primarily an underlying etiology</p>
          </list-item>
          <list-item>
            <p>Lifestyle modifications and combating risk variables (diabetes, hypertension, hyperlipidemia, sedentary lifestyles, obesity, cigarette smoking) and</p>
          </list-item>
          <list-item>
            <p>Aspirin for arteriosclerosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22965.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>
<bold>Types of Retinal Emboli:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Calcific emboli-&#x000a0;</bold>appear whitish, involve the central retinal artery, do not dissolve, and originate from cardiac valves or aorta calcification.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Fibrinoplatelet emboli- </bold>appear dull white within the retinal arteriole and arise from carotid thrombus.&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Talc emboli-&#x000a0;</bold>observed in patients with an intravenous drug and/or cocaine addiction, are relatively small and appear parafoveally.<xref ref-type="bibr" rid="article-22965.r26">[26]</xref> &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p>
<bold>Metastatic tumor cells&#x000a0;</bold>
<bold>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0;</bold>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Septic emboli</bold>- following bacterial endocarditis&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Fat emboli- </bold>occur<bold>&#x000a0;</bold>following long bone fractures and have concomitant scattered retinal microinfarcts and hemorrhages.<xref ref-type="bibr" rid="article-22965.r27">[27]</xref>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Amniotic fluid emboli&#x000a0;</bold><xref ref-type="bibr" rid="article-22965.r28">[28]</xref>
<bold>&#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;</bold></p>
          </list-item>
          <list-item>
            <p>
<bold>Air emboli&#x000a0;</bold>
<xref ref-type="bibr" rid="article-22965.r17">[17]</xref>
<xref ref-type="bibr" rid="article-22965.r29">[29]</xref>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22965.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The atheromatous disease of the ICA can be associated with HPs and is usually an indicator of potential stroke. Carotid stenosis increases stroke risk by 1.18 times for every 10% increase in stenosis. This risk of stroke rises &#x0003c;1% per year for a vessel that is &#x0003c;80% stenosed. On the contrary, a vessel &#x0003e;90% stenosed raises the stroke risk by 4.8% per year.</p>
        <p>Almost 75% of HPs are asymptomatic. Asymptomatic HP, however, is a poor predictor of future embolic events.<xref ref-type="bibr" rid="article-22965.r12">[12]</xref> However, 25% of these cohorts have carotid stenosis of &#x0003e;40%.<xref ref-type="bibr" rid="article-22965.r4">[4]</xref>&#x000a0;Symptomatic patients were more likely to harbor carotid stenosis &#x0003e;69% when compared with asymptomatic patients (25% vs 9.2%).<xref ref-type="bibr" rid="article-22965.r12">[12]</xref></p>
        <p>Patients with retinal cholesterol plaques had a higher incidence of stroke compared to their healthy counterparts (8.5% vs 0.8%).<xref ref-type="bibr" rid="article-22965.r12">[12]</xref><bold>&#x000a0;</bold>Cholesterol emboli have a 15% risk of mortality at&#x000a0;1 year, 29% at&#x000a0;3 years, and 54% at&#x000a0;7 years.<xref ref-type="bibr" rid="article-22965.r12">[12]</xref>&#x000a0;Hollenhorst observed that survival reduced by almost 15% and 40% at 1 and 8 years, respectively, in patients with retinal cholesterol embolism.<xref ref-type="bibr" rid="article-22965.r4">[4]</xref> These patients have increased odds of stroke-related deaths (hazard ratio, 2.61).<xref ref-type="bibr" rid="article-22965.r9">[9]</xref> The cumulative mortality was 56% with retinal emboli and 30% without retinal emboli.<xref ref-type="bibr" rid="article-22965.r4">[4]</xref> The risk of nonfatal myocardial infarction or vascular death was 7.7% (4.9% among controls).<xref ref-type="bibr" rid="article-22965.r30">[30]</xref></p>
        <p>Asymptomatic retinal cholesterol embolism is a risk variable for cerebral infarction.<xref ref-type="bibr" rid="article-22965.r30">[30]</xref> In a meta-analysis of 1343 patients with asymptomatic cholesterol emboli, 17.8% had a history of either cerebrovascular&#x000a0;accident (CVA) or TIAs at presentation. Twelve percent of these patients evolved to stroke, TIAs, or death during their follow-up.<xref ref-type="bibr" rid="article-22965.r31">[31]</xref> The evidence suggests that these patients warrant referral for medical optimization of pertinent cardiovascular risk factors.</p>
        <p>Currently, no recommendation exists to support&#x000a0;CEA in patients with HPs or retinal emboli alone.<xref ref-type="bibr" rid="article-22965.r31">[31]</xref> In&#x000a0;a study with 159 patients with CRAO, 284 with BRAO, and 85 with HP, mortality and cerebrovascular events were statistically significantly higher in only the CRAO and BRAO groups.</p>
      </sec>
      <sec id="article-22965.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of HPs include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Central retinal artery occlusion (CRAO)</p>
          </list-item>
          <list-item>
            <p>Branch retinal artery occlusion (BRAO)</p>
          </list-item>
          <list-item>
            <p>Ischemic strokes&#x000a0;<xref ref-type="bibr" rid="article-22965.r32">[32]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22965.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Deterrence and patient education play pivotal roles in addressing the implications of HPs and promoting vascular health. Clinicians engaging in deterrence strategies focus on identifying and managing risk factors associated with plaque formation, such as hypertension and atherosclerosis. By emphasizing lifestyle modifications, such as maintaining a heart-healthy diet, regular exercise, and smoking cessation, healthcare providers contribute to preventing HPs and related vascular issues.</p>
        <p>Concurrently, patient education is a cornerstone in empowering individuals with knowledge about the significance of these cholesterol emboli, potential risks, and available preventive measures. Educating patients on recognizing early symptoms, the importance of regular eye examinations, and adherence to prescribed medications fosters proactive involvement in their own healthcare, facilitating early detection and intervention to mitigate the impact of HPs on both ocular and systemic health. Together, deterrence and patient education create a foundation for informed decision-making and collaborative efforts in preserving overall vascular well-being.</p>
      </sec>
      <sec id="article-22965.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>HPs are yellow and refractile, typically located at the carotid artery bifurcation. They tend to&#x000a0;originate from carotid arteries or the aorta secondary to atherosclerotic lesions. The salient features include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>HPs are considered to be the most common form of emboli.</p>
          </list-item>
          <list-item>
            <p>HPs are a&#x000a0;common finding in the aging population.</p>
          </list-item>
          <list-item>
            <p>Approximately 75% of HPs seen in ophthalmic practice are asymptomatic.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-22965.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Even though there are several other causes of HPs, the most problematic diagnosis is atherosclerosis of the ICA. Often, the presence of an HP indicates an impending stroke, especially in older individuals.&#x000a0;Once an&#x000a0;HP has been diagnosed, the management generally involves a neurologist, ophthalmologist, cardiologist,&#x000a0;vascular surgeon, interventional radiologist, nurse, and pharmacist, functioning as a cohesive interprofessional team.</p>
        <p>Healthcare professionals managing patients with HPs need refined clinical skills for accurate diagnosis, including proficiency in ophthalmic examinations and the interpretation of retinal findings. Advanced practitioners, such as nurse practitioners and physician assistants, may play a crucial role in gathering comprehensive patient histories and conducting initial assessments.</p>
        <p>The patient should undergo a duplex ultrasound of the neck to determine the presence of&#x000a0;atherosclerotic disease at the carotid bifurcation. If the lesion is ulcerated and has &#x0003e;70% stenosis, the patient should be referred to a vascular surgeon or an interventional radiologist for either CEA or CAS. The patient should be encouraged to lower his blood pressure and cholesterol, discontinue smoking, and take aspirin while awaiting surgery. The nurse should educate the patient on possible stroke symptoms and when to return to the emergency room. When patients with carotid artery atherosclerosis are managed with elective surgery or stenting, the morbidity and mortality rates are &#x0003c;3%.<xref ref-type="bibr" rid="article-22965.r6">[6]</xref><xref ref-type="bibr" rid="article-22965.r10">[10]</xref> This type of interprofessional&#x000a0;collaboration will foster improved results.</p>
        <p>For patients with symptomatic HP, risk factors and cost-utility analyses are justified.<xref ref-type="bibr" rid="article-22965.r9">[9]</xref> Despite asymptomatic emboli, a medical referral is beneficial. HP with concurrent venous stasis retinopathy confers more conclusive evidence for the same.<xref ref-type="bibr" rid="article-22965.r33">[33]</xref> Positive predictive values of carotid stenosis for the ocular signs/symptoms of amaurosis fugax (18.2%), HPs (20.0%), and venous stasis retinopathy (20.0%) have been observed. Patients with carotid duplex showing ulcerated atheromatous plagues causing &#x0003e;70% stenosis should be referred for either CEA or CAS.</p>
        <p>Developing a cohesive strategy for managing patients with HPs involves aligning diagnostic and treatment approaches among the healthcare team. Physicians, in collaboration with pharmacists, can strategize effective medication regimens for managing underlying vascular conditions contributing to plaque formation. Advanced care practitioners may contribute to the development and implementation of patient care plans, ensuring continuity and consistency.</p>
        <p>Effective communication among healthcare professionals is essential for delivering patient-centered care. Team members must share relevant information, discuss treatment plans, and collaborate on interventions. Clear and open communication ensures that all team members are aligned in their understanding of the patient's condition and goals of care. A coordinated approach ensures that patients with HPs receive holistic and timely care across different healthcare settings.</p>
        <p>A&#x000a0;multidisciplinary approach involving physicians, advanced care practitioners, nurses, pharmacists, and other health professionals is crucial for enhancing patient-centered care, improving outcomes, ensuring patient safety, and optimizing team performance in managing patients with HPs. Effective communication and coordinated interprofessional team efforts contribute to a comprehensive, patient-focused care strategy.</p>
      </sec>
      <sec id="article-22965.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22965&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22965">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/hollenhorst-plaque/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=22965">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22965/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22965">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-22965.s16">
        <fig id="article-22965.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Hollenhorst Plaque Contributed by Dr Evan J Kaufman</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="HollenhorstPlaque__by__Dr.__Evan__Kaufman__at__UVA__department__of__Ophthalmology" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22965.s17">
        <fig id="article-22965.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Hollenhorst Plaque Contributed by Evan J Kaufman, OD, FAAO. University of Virginia, Department of Ophthalmology.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="1126945picture2" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-22965.s18">
        <fig id="article-22965.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Hollenhorst Plaque Contributed by Evan J Kaufman, OD, FAAO. University of Virginia, Department of Ophthalmology.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="1126945picture1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-22965.s19">
        <title>References</title>
        <ref id="article-22965.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Majstruk</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Giocanti-Aur&#x000e9;gan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Multimodal imaging of a Hollenhorst plaque].</article-title>
            <source>J Fr Ophtalmol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>39</volume>
            <issue>7</issue>
            <fpage>655</fpage>
            <page-range>655-6</page-range>
            <pub-id pub-id-type="pmid">27575573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coca</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Palau</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Embolic anterior ischemic optic neuropathy associated with a Hollenhorst plaque.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>133</volume>
            <issue>2</issue>
            <fpage>e143264</fpage>
            <pub-id pub-id-type="pmid">25674893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Terelak-Borys</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Skonieczna</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Grabska-Liberek</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Ocular ischemic syndrome - a systematic review.</article-title>
            <source>Med Sci Monit</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>18</volume>
            <issue>8</issue>
            <fpage>RA138</fpage>
            <page-range>RA138-144</page-range>
            <pub-id pub-id-type="pmid">22847215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graff-Radford</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boes</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>History of Hollenhorst plaques.</article-title>
            <source>Stroke</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>46</volume>
            <issue>4</issue>
            <fpage>e82</fpage>
            <page-range>e82-4</page-range>
            <pub-id pub-id-type="pmid">25593136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lawlor</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Bakri et al.: is carotid ultrasound necessary in the evaluation of the asymptomatic Hollenhorst plaque? (Ophthalmology 2013;120:2747-8).</article-title>
            <source>Ophthalmology</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>121</volume>
            <issue>9</issue>
            <fpage>e49</fpage>
            <page-range>e49-50</page-range>
            <pub-id pub-id-type="pmid">24907057</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bakri</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Luqman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pathik</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chandrasekaran</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Is carotid ultrasound necessary in the evaluation of the asymptomatic Hollenhorst plaque?</article-title>
            <source>Ophthalmology</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>120</volume>
            <issue>12</issue>
            <fpage>2747</fpage>
            <page-range>2747-2748.e1</page-range>
            <pub-id pub-id-type="pmid">24246827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Joachim</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Burlutsky</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kifley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>The Incidence and Progression of Age-Related Macular Degeneration over 15 Years: The Blue Mountains Eye Study.</article-title>
            <source>Ophthalmology</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>122</volume>
            <issue>12</issue>
            <fpage>2482</fpage>
            <page-range>2482-9</page-range>
            <pub-id pub-id-type="pmid">26383995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tokoyoda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tsujimoto</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sugiura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sezaki</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A hollenhorst plaque in cholesterol crystal embolism.</article-title>
            <source>Intern Med</source>
            <year>2012</year>
            <volume>51</volume>
            <issue>2</issue>
            <fpage>223</fpage>
            <pub-id pub-id-type="pmid">22246495</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klein</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Meuer</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Retinal emboli and stroke: the Beaver Dam Eye Study.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1999</year>
            <month>Aug</month>
            <volume>117</volume>
            <issue>8</issue>
            <fpage>1063</fpage>
            <page-range>1063-8</page-range>
            <pub-id pub-id-type="pmid">10448750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dunlap</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Kosmorsky</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Kashyap</surname>
                <given-names>VS</given-names>
              </name>
            </person-group>
            <article-title>The fate of patients with retinal artery occlusion and Hollenhorst plaque.</article-title>
            <source>J Vasc Surg</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>46</volume>
            <issue>6</issue>
            <fpage>1125</fpage>
            <page-range>1125-9</page-range>
            <pub-id pub-id-type="pmid">17950567</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitchell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Leeder</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Prevalence of asymptomatic retinal emboli in an Australian urban community.</article-title>
            <source>Stroke</source>
            <year>1997</year>
            <month>Jan</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-6</page-range>
            <pub-id pub-id-type="pmid">8996490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bakri</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Luqman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pathik</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chandrasekaran</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Is carotid ultrasound necessary in the clinical evaluation of the asymptomatic Hollenhorst plaque? (An American Ophthalmological Society thesis).</article-title>
            <source>Trans Am Ophthalmol Soc</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>111</volume>
            <fpage>17</fpage>
            <page-range>17-23</page-range>
            <pub-id pub-id-type="pmid">24072943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saric</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kronzon</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Cholesterol embolization syndrome.</article-title>
            <source>Curr Opin Cardiol</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>472</fpage>
            <page-range>472-9</page-range>
            <pub-id pub-id-type="pmid">21993354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolintz</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Carotid endarterectomy for ophthalmic manifestations: is it ever indicated?</article-title>
            <source>J Neuroophthalmol</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>299</fpage>
            <page-range>299-302</page-range>
            <pub-id pub-id-type="pmid">16340498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kassotis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Migrating Emboli in Branch Retinal Artery Occlusion.</article-title>
            <source>N Engl J Med</source>
            <year>2023</year>
            <month>Sep</month>
            <day>21</day>
            <volume>389</volume>
            <issue>12</issue>
            <fpage>e24</fpage>
            <pub-id pub-id-type="pmid">37721379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Filatov</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tom</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alexandrakis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Skolik</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Klassen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liggett</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Branch retinal artery occlusion associated with directional coronary atherectomy after percutaneous transluminal coronary angioplasty.</article-title>
            <source>Am J Ophthalmol</source>
            <year>1995</year>
            <month>Sep</month>
            <volume>120</volume>
            <issue>3</issue>
            <fpage>391</fpage>
            <page-range>391-3</page-range>
            <pub-id pub-id-type="pmid">7661214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garc&#x000ed;a-Arum&#x000ed;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Martinez-Castillo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Boixadera</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fonollosa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Corcostegui</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Surgical embolus removal in retinal artery occlusion.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>90</volume>
            <issue>10</issue>
            <fpage>1252</fpage>
            <page-range>1252-5</page-range>
            <pub-id pub-id-type="pmid">16854826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Magargal</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>The ocular ischemic syndrome. Clinical, fluorescein angiographic and carotid angiographic features.</article-title>
            <source>Int Ophthalmol</source>
            <year>1988</year>
            <month>Feb</month>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>239</fpage>
            <page-range>239-51</page-range>
            <pub-id pub-id-type="pmid">3182177</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saito</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Akiyama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mukai</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>ALTERATION OF OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN A PATIENT WITH OCULAR ISCHEMIC SYNDROME.</article-title>
            <source>Retin Cases Brief Rep</source>
            <year>2021</year>
            <month>Sep</month>
            <day>01</day>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>588</fpage>
            <page-range>588-592</page-range>
            <pub-id pub-id-type="pmid">30730456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huisa</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Stemer</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Zivin</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Atorvastatin in stroke: a review of SPARCL and subgroup analysis.</article-title>
            <source>Vasc Health Risk Manag</source>
            <year>2010</year>
            <month>Apr</month>
            <day>15</day>
            <volume>6</volume>
            <fpage>229</fpage>
            <page-range>229-36</page-range>
            <pub-id pub-id-type="pmid">20407630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Halliday</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bulbulia</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bonati</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Chester</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cradduck-Bamford</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>H</given-names>
              </name>
              <collab>ACST-2 Collaborative Group</collab>
            </person-group>
            <article-title>Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy.</article-title>
            <source>Lancet</source>
            <year>2021</year>
            <month>Sep</month>
            <day>18</day>
            <volume>398</volume>
            <issue>10305</issue>
            <fpage>1065</fpage>
            <page-range>1065-1073</page-range>
            <pub-id pub-id-type="pmid">34469763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferguson</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Eliasziw</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barr</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Clagett</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Haynes</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Finan</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Hachinski</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Barnett</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>The North American Symptomatic Carotid Endarterectomy Trial : surgical results in 1415 patients.</article-title>
            <source>Stroke</source>
            <year>1999</year>
            <month>Sep</month>
            <volume>30</volume>
            <issue>9</issue>
            <fpage>1751</fpage>
            <page-range>1751-8</page-range>
            <pub-id pub-id-type="pmid">10471419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <article-title>Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST).</article-title>
            <source>Lancet</source>
            <year>1998</year>
            <month>May</month>
            <day>09</day>
            <volume>351</volume>
            <issue>9113</issue>
            <fpage>1379</fpage>
            <page-range>1379-87</page-range>
            <pub-id pub-id-type="pmid">9593407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenfield</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Matsumura</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Chaturvedi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Riles</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ansel</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Metzger</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Wechsler</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jaff</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>W</given-names>
              </name>
              <collab>ACT I Investigators</collab>
            </person-group>
            <article-title>Randomized Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Mar</month>
            <day>17</day>
            <volume>374</volume>
            <issue>11</issue>
            <fpage>1011</fpage>
            <page-range>1011-20</page-range>
            <pub-id pub-id-type="pmid">26886419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <article-title>Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study.</article-title>
            <source>JAMA</source>
            <year>1995</year>
            <month>May</month>
            <day>10</day>
            <volume>273</volume>
            <issue>18</issue>
            <fpage>1421</fpage>
            <page-range>1421-8</page-range>
            <pub-id pub-id-type="pmid">7723155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luong</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Tsui</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Batra</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Zegans</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Endogenous endophthalmitis and other ocular manifestations of injection drug use.</article-title>
            <source>Curr Opin Ophthalmol</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>506</fpage>
            <page-range>506-512</page-range>
            <pub-id pub-id-type="pmid">31589187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>L&#x000f3;pez-Herrero</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz-Morales</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rueda-Rueda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Vicente</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Bilateral macular structural analysis after fat embolism syndrome.</article-title>
            <source>Arch Soc Esp Oftalmol (Engl Ed)</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>94</volume>
            <issue>12</issue>
            <fpage>e93</fpage>
            <page-range>e93-e94</page-range>
            <pub-id pub-id-type="pmid">31171386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Young</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Florine Magdelijns</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chervenak</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Amniotic fluid embolism: a reappraisal.</article-title>
            <source>J Perinat Med</source>
            <year>2024</year>
            <month>Feb</month>
            <day>26</day>
            <volume>52</volume>
            <issue>2</issue>
            <fpage>126</fpage>
            <page-range>126-135</page-range>
            <pub-id pub-id-type="pmid">38082418</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bradley</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Lantz</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Fatal systemic (paradoxical) air embolism diagnosed by postmortem funduscopy.</article-title>
            <source>J Forensic Sci</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>66</volume>
            <issue>5</issue>
            <fpage>2029</fpage>
            <page-range>2029-2034</page-range>
            <pub-id pub-id-type="pmid">34132391</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bruno</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Austin</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Qualls</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Vascular outcome in men with asymptomatic retinal cholesterol emboli. A cohort study.</article-title>
            <source>Ann Intern Med</source>
            <year>1995</year>
            <month>Feb</month>
            <day>15</day>
            <volume>122</volume>
            <issue>4</issue>
            <fpage>249</fpage>
            <page-range>249-53</page-range>
            <pub-id pub-id-type="pmid">7825759</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghoneim</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Westby</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Elsharkawi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Said</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Systematic review of the relationship between Hollenhorst plaques and cerebrovascular events.</article-title>
            <source>Vascular</source>
            <year>2024</year>
            <month>Aug</month>
            <volume>32</volume>
            <issue>4</issue>
            <fpage>784</fpage>
            <page-range>784-791</page-range>
            <pub-id pub-id-type="pmid">36914563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roskal-Wa&#x00142;ek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wa&#x00142;ek</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Biskup</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Odrobina</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mackiewicz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>G&#x00142;uszek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wo&#x0017c;akowska-Kap&#x00142;on</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Central and Branch Retinal Artery Occlusion-Do They Harbor the Same Risk of Further Ischemic Events?</article-title>
            <source>J Clin Med</source>
            <year>2021</year>
            <month>Jul</month>
            <day>13</day>
            <volume>10</volume>
            <issue>14</issue>
            <pub-id pub-id-type="pmid">34300257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22965.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCullough</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Reinert</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Hynan</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Albiston</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Inman</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Boyd</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>Welborn</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Clagett</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Modrall</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Ocular findings as predictors of carotid artery occlusive disease: is carotid imaging justified?</article-title>
            <source>J Vasc Surg</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>40</volume>
            <issue>2</issue>
            <fpage>279</fpage>
            <page-range>279-86</page-range>
            <pub-id pub-id-type="pmid">15297821</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
